Sponsored content brought to you by

Since its founding in 1995, The Ritedose Corporation has evolved from a small-scale operation into one of the world’s leading specialists in Blow-Fill-Seal (BFS) technology, a platform increasingly recognized for its role in the future of sterile drug manufacturing. Originally focused on contract manufacturing of sterile, single-dose packaging, Ritedose today leverages BFS to deliver innovation in drug delivery while maintaining a strict commitment to quality and regulatory excellence.

At its core, BFS integrates the forming, filling, and sealing of plastic containers into a fully automated, closed, aseptic process. By eliminating many of the risks inherent to traditional vial filling, BFS has become a preferred solution for ophthalmic products, inhaled medicines, injectable drugs, and other sensitive formulations. For biopharma developers, the technology offers both sterility assurance and patient convenience, two increasingly critical demands as the industry advances toward more complex therapies.

Ritedose’s culture reflects a patient-first philosophy, something CEO Jody Chastain underscores as central to the company’s mission. Throughout its Columbia, S.C. headquarters, photographs of patients serve as reminders that innovation is ultimately measured by its impact on those who depend on these therapies.

Scaling capacity and capabilities

To meet growing demand, Ritedose has made significant infrastructure investments over the past two years. Recent expansions include:

• A state-of-the-art logistics and distribution facility to streamline supply chain operations.
• A seventh Syntegon packaging line, doubling capacity for individually wrapped vial medications.
• An increase of 180-million-unit doses in sterile BFS production, supporting high-volume ophthalmic and respiratory therapies.
• Expansion of internal laboratory capabilities, including a larger analytical chemistry lab and an expansion of the existing microbiology lab designed to support advanced biologics and future therapies.

These investments not only expand capacity but also position Ritedose within the framework of Pharma 4.0, the industry’s shift toward connected, automated, and data-driven manufacturing.

An anchor in South Carolina’s life sciences ecosystem

Over the past three decades, Ritedose established itself as one of South Carolina’s largest and most entrenched life sciences companies, making the Columbia area a true anchor in the Palmetto State’s life science ecosystem.

Ritedose’s success isn’t something the company achieved on its own. It repeatedly partners with like-minded organizations to boost the entire region. By working with economic development partners locally—like the Columbia Area Development Partnership—and at the state level—with SCbio, South Carolina’s life sciences economic development organization—they collectively attract new businesses and improve the conditions for startups, emerging firms, and research institutions. Notably, the Columbia MSA has been recognized nationally as a leader in pharmaceutical employment growth, keeping pace with larger communities such as Chicago and San Diego.

Through workforce development programs with local schools and colleges, Ritedose also helps prepare the next generation of life sciences professionals, ensuring that growth in sterile manufacturing translates into long-term regional impact.

BFS, a platform for the future

The global BFS market is expanding rapidly, driven by the rise of injectables, biologics, and patient-centric drug delivery formats. BFS technology aligns with these trends by offering sterility, efficiency, and scalability, while also meeting evolving regulatory expectations. For Ritedose, this positions the company at the forefront of a critical segment of pharmaceutical manufacturing.

The increasing demand for sterile drug packaging, driven by the rapid growth of injectable pharmaceuticals and biologics, is a key factor propelling the BFS market. As the adoption of BFS continues to accelerate globally toward more agile, patient-focused production, Ritedose’s combination of innovation, experience, and regulatory compliance positions it, South Carolina, and the state’s capital, Columbia, at the forefront of this vital segment of drug manufacturing.

From pioneering BFS to maintaining an exemplary FDA record and 100% customer retention, Ritedose has earned national recognition for what the company manufactures as well as how they operate: with integrity, precision, and a relentless focus on quality.

To learn more about Ritedose’s CDMO capabilities, contact us at ritedose.com/cdmo

To learn more about scaling your business in Richland County, SC, scan the QR code.